There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS.^[1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xanamem and placebo groups. Xanamem was safe and well...